News & Updates
– Rebastinib in Combination with Paclitaxel Demonstrated Progression Free Survival of 9.1 months in Heavily Pretreated Patients with Platinum-Resistant Ovarian Cancer (PROC) – – Pivotal Phase 3 Study of Rebastinib plus Paclitaxel in PROC Planned to Initiate in 2022 Subject to Regulatory Feedback – – Updated Results for Vimseltinib Showed Objective Response Rate of 47%…
Read More
Excerpt from the Press Release: BOSTON, Sept. 16, 2021 (GLOBE NEWSWIRE) — SHEPHERD Therapeutics, a company dedicated to catalyzing lifesaving treatments for cancer patients, is pleased to present an e-poster of results from a computational approach to optimizing therapeutic selection for cancer patients using the Company’s proprietary precision-oncology DELVE platform, at the European Society for…
Read More
Local treatment with PD-1 and BRD4 dual-targeting INTASYL also showed complete resolution of tumors in vivo Excerpt from the Press Release: MARLBOROUGH, Mass., Sept. 16, 2021 /PRNewswire/ — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced results…
Read More
22% vs. 4% response rates with bavituximab-pembrolizumab in biomarker positive vs. negative patients using the Xerna™ TME Panel Excerpt from the Press Release: WALTHAM, Mass., Sept. 16, 2021 (GLOBE NEWSWIRE) — Oncxerna Therapeutics, Inc. (“OncXerna”), a precision medicine company using an innovative RNA-expression based biomarker platform to predict patient responses to its targeted oncology therapies,…
Read More
Excerpt from the Press Release: NTLA-5001 is Intellia’s first ex vivo candidate using its proprietary cell engineering process for the treatment of cancer to enter clinical study NTLA-5001 targets Wilms’ Tumor 1 (WT1), an overexpressed intracellular antigen on many hematologic malignancies and solid tumors Initiation of patient screening in Phase 1/2a study of NTLA-5001 expected…
Read More
Excerpt from the Press Release: — SQ3370, a novel investigational product that activates doxorubicin at the tumor site while minimizing systemic exposure, is the first click chemistry-based treatment to be used in humans — Initial Phase 1 data suggest more than 50 times greater exposure of doxorubicin in tumor versus plasma — No observed dose-limiting…
Read More
— Phase 1/2 study conducted at The University of Texas M.D. Anderson Cancer Center Excerpt from the Press Release: BURLINGAME, Calif., Sept. 16, 2021 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced the initiation of a Phase 1/2…
Read More
Excerpt from the Press Release: Interim results from ongoing Phase 1 dose-escalation study demonstrate safety and tolerability of repeat dosing with ACE1702, a novel, off-the-shelf natural killer cell therapy Initial results show potential for anti-tumor activity Dose escalation is continuing up to 15 billion cells per cycle to determine the recommended starting dose to further…
Read More
Excerpt from the Press Release: – Clinical activity observed in all three mesothelin-expressing tumor types treated – Gavo-cel disease control rate (DCR) 81% with tumor regression in 15 of 16 evaluable patients – Overall response rate (ORR) 31% in patients infused with gavo-cel following lymphodepletion – Meaningful survival benefit at 11.2 months for patients with…
Read More
Excerpt from the Press Release: CAMBRIDGE, Mass.–(BUSINESS WIRE)–Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced Health Canada has approved the New Drug Submission (NDS-CV) for SPIKEVAX™ (elasomeran mRNA vaccine), which has been known as COVID-19 Vaccine Moderna, for active immunization to prevent COVID-19 in individuals 12 years…
Read MoreRequest Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?